Quick Facts

Primary Use	Indication
Malaria Management	Used for specific cases of malaria caused by Plasmodium falciparum that are resistant to other treatments.
Babesiosis	May be used to treat babesiosis, an infection caused by parasites.

Квинель is a therapeutic option primarily used for the management of certain parasitic infections. The medication is indicated for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, particularly in geographical areas where resistance to standard antimalarial agents may be present. It is often reserved for situations where alternative therapies are not available or suitable.

In addition to malaria, Квинель may be used to address babesiosis, a condition that results from infection with Babesia parasites. The use of this drug is intended to reduce the severity of these infections. Healthcare providers determine the appropriate application of Квинель based on individual patient need and the nature of the condition. The medication is not approved or recommended for the treatment or prevention of nocturnal leg cramps.

Regulatory References

1. NIH MedlinePlus guidance on Quinine

Who Can and Cannot Use Квинель (Official Regulatory Information)

The eligibility profile for this medicine is strictly defined by regulatory authorities based on specific clinical and physiological states.

Populations for whom use is contraindicated: Use of this medicine is absolutely prohibited in patients with a documented prolongation of the QT interval, Myasthenia gravis, Optic neuritis, or Severe Hepatic Impairment (Child-Pugh C). It is also contraindicated for individuals with a known hypersensitivity to quinine or related compounds, and in those with a history of specific blood disorders associated with the drug, such as Thrombocytopenia or Blackwater fever.

---

Age and Condition-Specific Eligibility: The medicine is approved for use in Adults for its primary indication. For pediatric patients, safety and efficacy have not been established by some regulators for those under 16 years of age. Patients with Severe Chronic Renal Impairment require a reduction in dose and dosing frequency. Use requires caution in older adults and in patients with underlying cardiac conditions that may predispose them to QT-prolongation.

---

Pregnancy and Lactation Eligibility Status: Use during pregnancy is conditional; it is only recommended if the potential benefit justifies the risk to the fetus. The medicine is not recommended for the non-malarial indication during pregnancy. Caution must be exercised when administering to a nursing mother, as the drug is excreted in breast milk.

Interactions with other medicines and products

The official regulatory profile of Квинель (Quinine) documents several clinically significant interaction patterns, based on its pharmacokinetic and pharmacodynamic properties.

Pharmacokinetic and Metabolic Interactions

Quinine is classified as an inhibitor of CYP3A4 and P-glycoprotein (P-gp). This characteristic causes a documented increase in the systemic exposure of co-administered medicines that are substrates of these pathways, notably Digoxin. Quinine's own plasma concentration is subject to alteration, with Cimetidine (an inhibitor) increasing its levels and Rifampicin (an inducer) decreasing its levels through effects on the CYP3A4/2C8 metabolic system.

Pharmacodynamic and Timing Restrictions

Regulatory documentation emphasizes the high risk of a pharmacodynamic interaction with other QT-prolonging medicinal products, resulting in an additive effect on the QTc interval. Additionally, Quinine can potentiate the effects of Neuromuscular Blocking Agents and Anticoagulants such as Warfarin.

Formal restrictions apply to co-administration with Mefloquine; sequential administration typically requires a minimum separation of 12 hours to manage the risk of serious neuropsychiatric events. Administration with Aluminum-Containing Antacids may require approximately a 2-hour separation to avoid reduced Quinine absorption.

Hepatic impairment is noted as a population-specific consideration where reduced clearance can amplify the risk and severity of exposure-related interactions.

How Квинель Works: Mechanism of Action

---

Targeting Central Arousal Receptors

The drug's primary action involves its selective engagement with Alpha-2 adrenergic (alpha2) and H1 histamine (H1) receptors within the brain. It functions as a partial agonist at alpha2ARs and an antagonist at H1Rs, initiating dual-pathway modulation that results in subsequent physiological adjustments.

---

Modulating Norepinephrine Signaling

The alpha2 agonism targets presynaptic alpha2 autoreceptors, which subsequently reduces the release of the activating neurotransmitter norepinephrine (NE) from the nerve terminal. This molecular suppression of NE output initiates a cascade that affects central arousal pathways and modifies sympathetic outflow.

---

⬇️ Influencing Central Nervous System Excitability

By simultaneously reducing noradrenergic activity and blocking the excitatory effects of histamine via H1 antagonism, the drug alters the balance of the central nervous system toward an inhibitory state. This process produces physiological changes characterized by reduced central nervous system excitability.

Квинель (Quinine) is administered either orally or via slow intravenous (IV) infusion, depending on the severity of the infection. For the treatment of uncomplicated infections, the oral route is standard. The typical adult oral dosing regimen is 648 mg of the quinine salt taken every 8 hours (three times daily), though some guidelines specify a dose of 600 mg.

It is a requirement that the oral form be administered with food to minimize gastrointestinal discomfort. The medication must be continued for a full course duration of 7 days and administered concurrently with a second anti-infective agent. If a dose is missed, instructions advise taking it as soon as remembered, but double doses are prohibited.

The IV infusion route is used for severe or complicated infections and requires administration in a supervised setting. The injectable solution must be diluted in a compatible solution and delivered via slow infusion over several hours, never as a rapid injection. Guidelines also mandate dose adjustments for specific populations; for example, patients with severe chronic kidney impairment require a reduced maintenance dose of 324 mg every 12 hours after the initial loading dose. This loading dose must be omitted if the patient has received quinine or mefloquine within the previous 24 hours.

Research Evidence / Overview of Studies for Квинель (Citicoline)

---

Evidence for Use in Acute Ischemic Stroke

Research examined the compound in adult patients following an acute ischemic stroke, monitoring outcomes related to daily functioning and neurological status. These studies focused primarily on Randomized Controlled Trials (RCTs). The outcomes reflecting daily functioning or activity level were measured using standardized tools like the Modified Rankin Scale and the Barthel Index to evaluate functional independence.

The findings were mixed across the major trials. While some smaller studies described patterns observed in the study populations, the largest clinical trials reported limited to no difference in key functional endpoints when compared to control groups. Research highlights changes measured during the study period, but the data do not establish a consistent pattern related to functional recovery.

What remains uncertain is how the medicine may be associated with changes in the course of recovery. The inconsistency of findings between large-scale pivotal trials is a key limitation, and later systematic reviews have indicated that the certainty remains low due to high risk of bias cited in some earlier studies. The primary follow-up durations were often limited to 90 days, meaning long-term effects are not fully established.

---

Evidence for Cognitive and Age-Related Brain Changes

Research examined the compound's use in conditions characterized by fluctuating or episodic manifestations, particularly in older adults experiencing age-associated memory challenges or vascular cognitive impairment. The research scenarios included randomized, controlled studies that monitored physiological strain over intermediate durations. Researchers used specialized psychological test batteries to measure outcomes related to systemic or functional imbalance, such as attention, memory, and executive function.

The findings describe patterns observed in the studies where some controlled trials reported measurements of specific cognitive domains compared to baseline or placebo. However, the available evidence quality varies across studies. Much of the evidence is limited due to sample sizes were modest in many trials and the use of differing cognitive tests, which contributes to study heterogeneity.

---

What is Still Uncertain About Квинель's Research Base

Despite the volume of research, several critical areas remain uncertain. The most significant gap is the inconsistency of findings across large-scale randomized trials, particularly for stroke recovery. This makes it difficult to draw clear, consistent conclusions supported by regulatory documentation. Additionally, long-term effects are not fully established across any of the studied conditions, and comparative evidence is lacking to fully contextualize the compound's place for its intended research context.

Common questions about Квинель (FAQ)

Q: What is Квинель and what is it used for?

Квинель is a brand name for a medicine that contains the active ingredient quinagolide. It is classified as a dopamine agonist. It works by mimicking the action of the natural chemical dopamine in the brain, specifically affecting the pituitary gland.

The main use of quinagolide is to lower high levels of the hormone prolactin (hyperprolactinemia) in the blood. Prolactin is a hormone that stimulates milk production. High levels can cause problems in both men and women, such as menstrual irregularities, infertility, abnormal milk production (galactorrhea), and sexual dysfunction. Quinagolide helps to inhibit the production and release of prolactin, normalizing its levels.

---

Q: How should I take Квинель?

Квинель should be taken exactly as prescribed by your healthcare provider. The usual practice is to start with a very low dose, often called a starter dose, and then gradually increase it (titration) until the optimal dose is reached. This helps to reduce the likelihood and severity of side effects.

• Starter Dose: You typically take a very small dose for the first few days (e.g., the 25 mcg tablet).
• Maintenance Dose: The dose is then increased to the recommended maintenance dose, which is usually taken once a day.

It is generally recommended to take the tablet once daily, at bedtime, with a light snack or meal. Taking it at bedtime can help minimize certain side effects, like dizziness or orthostatic hypotension (a drop in blood pressure upon standing).

---

Q: What are the possible side effects of Квинель?

Like all medicines, Квинель can cause side effects, although not everyone gets them. Side effects are typically most common at the beginning of treatment and often lessen or disappear as your body adjusts to the medication and the dose is gradually increased.

Common side effects often include:

• Dizziness or lightheadedness
• Headache
• Nausea
• Vomiting
• Fatigue or tiredness
• Insomnia (difficulty sleeping)

Less common, but serious side effects that require immediate medical attention include:

• Orthostatic hypotension (a sudden drop in blood pressure when moving from lying down or sitting to standing, which can cause fainting).
• Psychiatric changes (e.g., changes in mood, agitation, confusion).

If you experience any severe or persistent side effects, you must contact your healthcare provider.

---

Q: Can I drink alcohol while taking Квинель?

It is generally advised to limit or avoid alcohol while taking Квинель. Both alcohol and Квинель can cause side effects like dizziness, drowsiness, and lightheadedness.

Combining the two can potentially increase the severity of these effects, especially dizziness and sedation, which may impair your ability to drive or operate machinery safely. Discuss any alcohol consumption with your doctor.

---

Q: Can Квинель affect my ability to drive or operate machinery?

Квинель, especially at the start of treatment or after a dose increase, can cause side effects such as dizziness, lightheadedness, and drowsiness.

These effects may significantly impair your ability to safely drive a vehicle or operate complex machinery. It is essential to understand how the medicine affects you before engaging in such activities. If you experience drowsiness or sudden sleepiness, you must avoid driving or other hazardous activities and consult your doctor.

---

Q: What should I do if I miss a dose of Квинель?

If you miss a dose of Квинель, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule.

Do not double the dose to make up for a missed tablet. Taking more than the prescribed amount can increase the risk of side effects. If you are unsure what to do, contact your healthcare provider for advice.

---

Q: How long will I need to take Квинель?

The duration of treatment with Квинель is highly individualized and depends on the specific reason you are taking it and how well your prolactin levels respond to the medication.

Your healthcare provider will monitor your prolactin levels and symptoms regularly. Do not stop taking Квинель suddenly or change your dosage without first discussing it with your doctor, as this could cause your prolactin levels to rise again.

How to Store and Dispose of Квинель (Quinine)

The storage of Квинель must strictly adhere to regulatory requirements to ensure product stability and safety.

Storage and Handling Requirements

The medicine should be stored in a cool, dry, and well-ventilated place, with mandatory protection from light and moisture. The product container must be kept tightly closed to prevent environmental degradation and minimize the risk of the active substance breaking down due to heat exposure.

Safety and Disposal

It is required to keep the medication out of the sight and reach of children and secured against unauthorized access. Disposal of any unused or expired Квинель must be managed through an approved pharmaceutical waste program. The medicine must not be flushed down the toilet or disposed of in the drain or household trash, as this is prohibited to protect the environment.